Phacilitate Leaders World

Immunotherapy: Extending its reach, predicting responses

Immunotherapy: Extending its reach, predicting responses

View on-demand our webinar exploring:

  • Optimal application of combinations, aided by appropriate patient selection based on predictive biomarkers
  • Understanding the interactions between the immune system and tumours, which deploy various mechanisms to disrupt key processes, and targeting distinct checkpoint pathways
  • Where is the potential for new clinical application across broad patient populations?

Speakers include:

  • Art Krieg, CEO, Checkmate Pharmaceuticals
  • Dr Emmett Schmidt, Executive Director, Clinical Research, Merck Sharp & Dohme
  • Dr Richard Murray, CEO, Jounce Therapeutics
  • Dr Andrea Van Elsas, Chief Scientific Officer, Aduro Biotech Europe



immunotherapy webinar
Originally Broadcasted: Friday, September 2 2016, 2:00 PM BST

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman